Positron emission tomography (PET) and endogenous competition paradigms are widely used for studying 10 neuroreceptor activation in humans in vivo. Critical aspects of this changes in cerebral blood found triggered by the 11 experimentation, such as amphetamine administration, could influence both tracer delivery and washout, thus biasing the results. 12 A recent study tested this assumption in baboons by measuring of radiotracer binding with PET while measuring cerebral blood 13 flow with arterial spin labeled functional magnetic resonance imaging. Cerebral blood flow was modulated by CO 2 inhalation. 14 Hypercapnia led to substantial alterations in blood flow with no detectable alteration in binding of the reversibly binding 15 radiotracers [ 11 C]raclopride and [ 18 F]fallypride. These results rule out a serious confound for the endogenous competition 16 paradigm, and demonstrate the importance of simultaneous PET and MRI measurements when studying brain function. 17
EMISSION TOMOGRAPHY 20 In the late 1980s, measuring cerebral blood flow (CBF) changes 21 associated with neuronal activity with positron emission 22 tomography (PET) and [ 15 O]-H 2 O stood as the state-of the 23 art method for quantifying brain function and mapping the 24 functional localization of motor, cognitive, and emotional 25 processes in the brain. This approach was soon mostly replaced 26 by the development of the blood-oxygenation dependent 27 (BOLD) contrast imaging for functional MRI by Ogawa and 28 colleagues in the 1990s. Even though BOLD signal has a complex 29 relationship with actual neuronal spiking, the fact that [ 15 O]-30 H 2 O PET provides quantitative measurement of CBF was not 31 enough to motivate the use this approach in "activation" studies 32 of global neuronal activity, given its complexity, financial costs, 33 and invasiveness. 34 Yet up to date, PET remains the only available technique for 35 whole-brain in vivo measurement of the availability and 36 displacement or activation of specific neuroreceptors. Whereas 37 BOLD contrast imaging yields an overall index of brain activation 38 irrespective of the involved neurotransmitters, high molecular 39 resolution of PET makes it a preferred tool for quantifying 40 activation of specific neuroreceptor and transmitter systems. In f1 41 this kind of activation or "challenge" studies ( Figure 1A ), 42 neuroreceptor availability is measured under two conditions: 43 Once during a baseline and once during or immediately after a 44 pharmacological or behavioral challenge, such as amphetamine 45 administration or pain stressor. The radioligand is assumed to 46 compete with the endogenous radioligand for occupancy at the 47 neuroreceptors, hence altered endogenous neurotransmitter 48 levels can be measured by monitoring changes in the radioligand 49 binding with the PET camera. 
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Viewpoint DOI: 10.1021/acschemneuro.7b00489 ACS Chem. Neurosci. XXXX, XXX, XXX−XXX B 93 repeatedly during the scan to induced change in CBF, and also 94 separately at the beginning and at the end of the scan. This 95 allowed testing whether radioactivity uptake would be 96 confounded by concomitant hypercapnia-induced changes in 97 perfusion. 98 As expected, hypercapnia increased CBF by about 2.5-fold, 99 which coincided with increased end-tidal CO 2 . Importantly, 100 increased perfusion occurred without any noticeable concom-f2 101 itant change in uptake of either radiotracer binding (Figure 2) . 102 Radioligand binding was unaltered regardless of whether 103 increased perfusion occurred before or after equilibrium of 104 radioactivity uptake. To date, this pattern of findings represents 105 the most reassuring demonstration of the independence of 106 reversible radiotracer binding and brain perfusion, providing 107 reassurance that prior work using the challenge paradigm were 108 not likely confounded by altered perfusion. This study also 109 demonstrates the power of simultaneous PET-fMRI measure-110 ments; this type of study would not have been possible by other 111 means, such as consecutive measurements of perfusion and 112 radiotracer binding. 113 ■ OUTSTANDING QUESTIONS 114 The convincing nature of the results notwithstanding, several 115 questions remain open. First, it must be noted that the 116 simultaneous PET-fMRI paradigm of Sander and colleagues 117 rely on delivering the hypercapnia challenge and the control 118 condition within a single PET scan, without a fully independent 119 control scan. Thus, one could question the sensitivity of PET for 120 picking up short-term hyperperfusion-induced changes within 121 such design. Also, we do not know how well these results 122 translate to the different approaches and methods are being used 123 for PET displacement studies. We and others favor the simple 124 single-bolus injections with single scan per condition, while some 125 employ a bolus injection followed by continuous radiotracer 126 infusion to achieve steady-state radioligand binding. Although, 127 the relative sensitivity of these approaches to blood flow remains 128 to be tested, the fact that even very large blood flow changes 129 produced no measurable changes in the PET data reassures that 130 blood flow does not affect the quantification of these tracers. 131 The degree to which these results are generalizable to other 132 radiotracers also remains unknown. Displacement studies 133 typically employ reversibly binding radioligands, such as 134 [ 11 C]raclopride and [ 18 F]fallypride assessed here. Because even 135 these two radioligands have very different pharmacokinetics, 136 these results likely translate to other reversibly binding 137 radioligands as well. Another remaining question in this context 138 is how well these nonhuman-primate results translate to humans. 139 Yet, given the bulk of evidence from simulations and observation 140 from human PET data up to date, 3 we think these results can 141 safely be assumed to hold in humans as well. 142 All in all, these results are reassuring to the PET researchers 143 using the challenge paradigm, ruling out one of the most widely 144 (2) 165 Saanijoki, T., Tuominen, L., Tuulari, J. J., Nummenmaa, L., 166 Arponen, E., Kalliokoski, K., and Hirvonen, J. (2017) 
